Ema committee for medicinal products for human use (chmp) adopts positive opinion recommending authorization for the use of moderna's omicron-targeting bivalent booster in the european union

Study results show mrna-1273.214 has demonstrated significantly higher antibody titers against omicron ba.1 and ba.4/5 subvariants when compared with mrna-1273 positive recommendation follows recent amendment to european commission (ec) covid-19 vaccine agreement to supply omicron-targeting bivalent candidates in addition to the chmp positive opinion, moderna has received approvals for mrna-1273.214 in australia, switzerland, and the uk cambridge, ma / accesswire / september 1, 2022 / moderna, inc . (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending conditional marketing authorization for spikevax bivalent original/omicron ba.1 (mrna-1273.214), the company's next-generation bivalent vaccine candidate that contains mrna-1273 and a vaccine candidate targeting the omicron variant of concern (ba.1).
MRNA Ratings Summary
MRNA Quant Ranking